<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of polymyalgia rheumatica</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of polymyalgia rheumatica</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of polymyalgia rheumatica</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlo Salvarani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francesco Muratore, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth J Warrington, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized clinically by aching and morning stiffness about the shoulders, hip girdle, and neck. It can be associated with giant cell arteritis (GCA, also known as Horton disease, Horton giant cell arteritis, and temporal arteritis); the two disorders may represent different manifestations of a shared disease process. (See  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica"</a>.)</p><p>The treatment of PMR will be reviewed here. The clinical manifestations of PMR, as well as the clinical manifestations, diagnosis, and treatment of GCA, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica"</a> and  <a class="medical medical_review" href="/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a> and  <a class="medical medical_review" href="/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a> and  <a class="medical medical_review" href="/d/html/8240.html" rel="external">"Treatment of giant cell arteritis"</a>.)</p><p class="headingAnchor" id="H3964215107"><span class="h1">INITIAL MANAGEMENT</span></p><p class="headingAnchor" id="H2"><span class="h2">Overall approach</span><span class="headingEndMark"> — </span>Initial treatment with low-dose glucocorticoids is recommended for all patients diagnosed with polymyalgia rheumatica (PMR)  (<a class="graphic graphic_algorithm graphicRef130045" href="/d/graphic/130045.html" rel="external">algorithm 1</a>). The primary goal of treatment is the relief of symptoms. The initial dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> needed to alleviate musculoskeletal symptoms in PMR is lower than that used to control the vascular inflammation associated with giant cell arteritis (GCA) (see  <a class="medical medical_review" href="/d/html/8240.html" rel="external">"Treatment of giant cell arteritis"</a>). Treatment has not been shown to improve prognosis or prevent progression to GCA.</p><p>The therapeutic response to low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> is characteristically brisk and complete. Subsequently, the glucocorticoid dose is gradually reduced. The duration of treatment varies among patients. Many patients can be tapered off glucocorticoids in one to two years, though the need for longer courses of treatment is not uncommon.</p><p class="headingAnchor" id="H5"><span class="h2">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Though there are no randomized trials comparing <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> with placebo or other single agents, the efficacy of glucocorticoids for the management of PMR has been established by decades of clinical experience and observational studies. Patients are unlikely to respond to other therapies and do not spontaneously remit. Despite the general consensus around the approach to therapy, there is no universally accepted approach to initial glucocorticoid dosing, maintenance therapy, or dose reduction.</p><p class="headingAnchor" id="H2923669090"><span class="h3">Initial dose</span><span class="headingEndMark"> — </span>In most patients, an initial <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose of 15 mg/day (or equivalent) given orally is suggested. The starting dose can be modified depending on the patient's weight, severity of symptoms, and comorbidities such as diabetes mellitus, severe hypertension, or heart failure. Lower doses of 7.5 to 10 mg/day may suffice in smaller patients with mild symptoms or brittle diabetes. By comparison, an initial dose of 20 or occasionally 25 mg/day may be appropriate in an otherwise healthy patient with severe aching and stiffness and constitutional symptoms. Patients typically respond quickly. Occasional patients report dramatic symptomatic relief after only a single glucocorticoid dose, and the majority of patients experience substantial improvement within days of starting treatment, even in the context of longstanding symptoms.</p><p>If symptoms are not significantly improved within one week of initiating therapy, the <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose can be escalated to 20 mg/day. A divided dose of prednisone (twice daily) can be useful for securing symptomatic relief if a single morning dose is not fully effective. A salient feature of PMR is the intensity of the gel phenomenon, which refers to a worsening of pain and stiffness with inactivity. In consequence, some patients find that a single morning dose of prednisone will not prevent a significant recrudescence of aching and stiffness at night and the following morning; in such patients, split-dose glucocorticoid treatment can be an effective therapeutic maneuver. The administration of prednisone in divided doses for PMR has not been formally studied.</p><p>There are limited data regarding the optimal starting dose of glucocorticoids, and practice is largely based on experience by experts and conclusions drawn from systematic reviews. A systematic review of evidence comparing different starting doses of glucocorticoids identified one randomized trial and seven observational studies [<a href="#rid1">1</a>]. The randomized trial of 39 patients with PMR found that patients treated with starting doses of 20 mg/day were less likely to flare within two months compared with those who were started on <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 10 mg (11 versus 65 percent of patients, respectively) [<a href="#rid2">2</a>]. The observational studies included in the analysis, however, showed inconsistent results in terms of the effect of higher versus lower starting doses of prednisone on rates of relapse and remission [<a href="#rid3">3-9</a>]. Nonetheless, all patients experienced some degree of symptom improvement with glucocorticoids. Another study suggested that the optimal initial dose may depend on body weight [<a href="#rid10">10</a>].</p><p>Although the response to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is typically described as brisk, two prospective studies have described slower responses to treatment with low-dose glucocorticoids. In one study, 26 percent of 129 patients reported continued proximal myalgias after three weeks of 15 mg/day of <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> [<a href="#rid11">11</a>], and in another study, 29 percent of 125 patients did not achieve a definition for a complete response to low-dose glucocorticoids at four weeks [<a href="#rid12">12</a>]. Nevertheless, the usually prompt and impressive therapeutic response to low-dose glucocorticoids remains a widely appreciated feature of PMR.</p><p>Alternate routes of administration of glucocorticoids have been studied but are generally not used in clinical practice. A double-blind randomized trial of intramuscular <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>, 120 mg every three weeks, versus oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> showed comparable remission rates and lower cumulative glucocorticoid doses in the methylprednisolone-treated group [<a href="#rid13">13</a>]. In a subset of patients, bilateral shoulder injections with glucocorticoids given weekly for four weeks may alleviate symptoms of PMR for up to seven months [<a href="#rid14">14</a>]. Thus, in milder cases, or in patients with several comorbidities, intramuscular or intraarticular (shoulder) glucocorticoid injections may be a reasonable alternative.</p><p>Practically all patients with PMR alone will respond to 12.5 to 20 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or, at most, 25 mg/day. Persistent aching and stiffness mandate pursuit of an alternative diagnosis. If musculoskeletal symptoms subside but fevers and other constitutional symptoms continue, underlying GCA or another illness should be considered. (See  <a class="medical medical_review" href="/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis", section on 'Differential diagnosis'</a>.)</p><p>This approach is generally consistent with published guidelines [<a href="#rid15">15-17</a>] and expert reviews [<a href="#rid1">1,18-21</a>]. Guidelines proposed by a collaboration of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) suggested the use of the lowest effective dose within a range of 12.5 to 25 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> equivalent, administered once daily [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H2729637700"><span class="h3">Monitoring response to therapy</span></p><p class="headingAnchor" id="H1766810075"><span class="h4">Clinical assessment</span><span class="headingEndMark"> — </span>The initial clinical response to therapy should be closely monitored. After one to two weeks, it is reasonable to seek some form of communication with the patient, either by phone or secure electronic communication, for the purpose of determining whether there has been the prompt symptomatic response to treatment characteristic of PMR, or whether adjustments in glucocorticoid dosing are needed. A formal return visit at four to eight weeks should be arranged in order to confirm resolution of symptoms and to outline a plan for glucocorticoid tapering, or, if symptoms persist, to initiate the workup for an alternative diagnosis. Subsequent follow-up visits can be scheduled at intervals between three to six months, depending on the clinical course of the individual patient. At each visit, patients should be questioned as to symptoms referable to PMR and GCA and should be assessed for glucocorticoid side effects (see <a class="local">'Minimizing risks of glucocorticoid therapy'</a> below). Patients must also be educated about the diagnosis of GCA once the initial diagnosis of PMR is confirmed and instructed to promptly report symptoms suggestive of this diagnosis. (See <a class="local">'Assessment for GCA'</a> below and  <a class="medical medical_review" href="/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a>.)</p><p class="headingAnchor" id="H1615321126"><span class="h4">Laboratory testing</span><span class="headingEndMark"> — </span>Elevations in the acute phase reactants (erythrocyte sedimentation rate [ESR] and serum C-reactive protein [CRP]) generally revert to normal with low doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in association with symptomatic improvement. Some data [<a href="#rid22">22</a>] and clinical experience indicate that the CRP appears to be a more sensitive and reliable index of disease activity compared with the ESR, though controlled studies in this regard are lacking.</p><p>The acute phase reactants should be checked at the time of the patient's first return visit following the diagnosis of PMR. The ESR and CRP are then repeated as indicated every three to six months during glucocorticoid therapy, noting that patients with recurrent relapses often require more frequent laboratory monitoring. Repeat determinations are indicated for the assessment of recurring symptoms, but minor fluctuations in the ESR or CRP, in the absence of symptoms directly attributable to PMR, are not of themselves sufficient reason for increasing the glucocorticoid dose.</p><p>Continued or recurrent high levels of the acute phase reactants in the asymptomatic patient should raise concern about concurrent GCA (see <a class="local">'Assessment for GCA'</a> below). Other explanations for such elevations, such as coincidental malignancy or infection, should not be overlooked. (See  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica", section on 'Differential diagnosis'</a>.)</p><p>Interleukin (IL)-6 has also been shown to correlate with disease activity [<a href="#rid23">23,24</a>]. As assays are not available in most laboratories, however, a role for IL-6 measurement in routine clinical care has not been established. Fibrinogen levels have also been reported to track with disease activity in patients with PMR but, in most settings, are not used routinely for assessment of the disease course [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1520427889"><span class="h3">Glucocorticoid tapering</span><span class="headingEndMark"> — </span>As is the case with the starting dose of glucocorticoids, there is no consensus regarding an optimal tapering regimen. In general, the glucocorticoid dose that controls symptoms is maintained for two to four weeks after aching and stiffness have resolved. The dose is then reduced by small decrements every two to four weeks thereafter as tolerated to the minimum amount needed to maintain suppression of symptoms. For example, in patients receiving over 10 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>/day, the dose can be lowered by 2.5 mg/day decrements every two to four weeks. Below 10 mg/day, the use of 1 mg decrements is advised because of the characteristic and distinctive sensitivity of the symptoms of PMR to even minor changes in the glucocorticoid dose. Dose reductions by 1 mg per month are reasonable, provided there are no flares. With this regimen, patients without a relapse in symptoms will have been treated for approximately one year. (See <a class="local">'Duration of therapy'</a> below.)</p><p class="headingAnchor" id="H199444930"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>In most patients, PMR runs a self-limited course, and glucocorticoids can eventually be discontinued. In about one-half of patients, treatment can be stopped after one to two years [<a href="#rid26">26</a>]. Other patients require continuation of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for longer periods of time, commonly at stable doses of 5 mg/day or less. At one center, the median duration of some glucocorticoid therapy was 37 months [<a href="#rid27">27</a>]. Another study found that one-third of patients required management with glucocorticoids for more than six years [<a href="#rid28">28</a>]. Clinical inertia likely accounts for a protracted course of low-dose glucocorticoid treatment in some patients.</p><p>Practically, there appear to be two broad subgroups of PMR. In one, glucocorticoids can be rather uneventfully tapered off over a year or two, while in another, a relapsing course requires longer treatment.</p><p class="headingAnchor" id="H565772559"><span class="h2">Additional management considerations</span></p><p class="headingAnchor" id="H833730139"><span class="h3">Assessment for GCA</span><span class="headingEndMark"> — </span>GCA can occur before, concurrent with, or after the diagnosis of PMR. All patients with PMR should be carefully assessed for symptoms and signs referable to GCA at initial diagnosis and then routinely screened for underlying GCA at subsequent visits. (See  <a class="medical medical_review" href="/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a>.)</p><p>Estimates of the overall occurrence of GCA in PMR patients vary; clinical practice suggests that about 10 percent of patients with PMR are at some point diagnosed with GCA. PMR can appear for the first time during the treatment of GCA as glucocorticoids are tapered to low doses. In about one-half of cases of GCA, the initial clinical presentation includes PMR. Late GCA, developing after an initial diagnosis of PMR, occurs in 7 to 10 percent of patients [<a href="#rid29">29,30</a>]; the duration between initial diagnosis of PMR and subsequent diagnosis of GCA ranges from months to years. GCA can occur despite prior or ongoing low-dose glucocorticoid treatment.</p><p>As risk factors for the occurrence of GCA have not been defined in patients with PMR, sustained and regular clinical vigilance for GCA is essential. In an otherwise asymptomatic PMR patient with unexplained elevations of the acute phase reactants, patients should be evaluated for the possibility of GCA, with regard to either cranial arteritis or large vessel vasculitis.</p><p>At any time during the disease course, patients with PMR who develop sudden vision loss, the most dreaded complication of GCA, should be immediately treated with adequate doses of glucocorticoids and evaluated for underlying GCA in order to prevent further cranial ischemic events [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/8240.html" rel="external">"Treatment of giant cell arteritis"</a>.)</p><p class="headingAnchor" id="H3773653086"><span class="h3">Minimizing risks of glucocorticoid therapy</span><span class="headingEndMark"> — </span>Prevention of and monitoring for side effects, including osteoporosis, glucose intolerance, hypertension, glaucoma, and cataracts, are essential components of a comprehensive management program for PMR (see  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>). Case series and disease cohorts have described and documented such side effects. In two studies, patients with PMR managed with glucocorticoids incurred at least one adverse event attributable to treatment in 81 of 124 patients (65 percent) and 95 of 222 patients (43 percent) [<a href="#rid32">32,33</a>].</p><p>In an inception cohort of 359 patients with PMR compared with population-based controls, however, only cataracts were found to be more common in PMR than comparators [<a href="#rid34">34</a>]. The rates of glucocorticoid-related diabetes mellitus, hypertension, hyperlipidemia, and fragility fractures were not significantly different between the two groups. It should be observed that this and other studies on adverse events from glucocorticoid treatment for PMR have not tracked side effects that are frequently more problematic in practice, such as facial hirsutism, Cushingoid facies, weight gain, and capillary fragility. Capillary fragility can result in widespread ecchymoses and slowly healing lacerations, especially in patients on concurrent treatment with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or anticoagulants.</p><p>As most patients with PMR require glucocorticoid treatment for more than several months, standard guidelines for prevention of glucocorticoid-induced osteoporosis should be followed, including an assessment of bone mineral density at or near the time <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is begun, treatment with calcium and vitamin D supplementation, and, when indicated by treatment guidelines, prophylactic use of bisphosphonates. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p>Blood pressures should be monitored regularly, and, when indicated, glycosylated hemoglobin (hemoglobin A1c) levels should be obtained to monitor for the development of diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/1761.html" rel="external">"Screening for type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H2904551732"><span class="h3">Indications for referral to a rheumatologist</span><span class="headingEndMark"> — </span>PMR is common and, depending on prevailing clinical practices, can often fall under the purview of a generalist. Referral to a rheumatologist should be considered if there are atypical features (eg, younger patients, presenting fever), prominent peripheral arthritis, an inadequate response to initial glucocorticoid treatment, or difficulties with glucocorticoid tapering.</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT OF RELAPSING OR RECURRENT DISEASE</span></p><p class="headingAnchor" id="H88585559"><span class="h2">Patients with recurrent symptoms</span><span class="headingEndMark"> — </span>Relapses of aching and morning stiffness are frequent during the course of the glucocorticoid taper and have been reported in over 50 percent of patients [<a href="#rid3">3,35,36</a>]. In clinical practice, relapses during tapering are more the rule than the exception. Relapses are most common in the first one to two years of treatment and at <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> doses under 10 mg/day [<a href="#rid36">36</a>]. As would be expected, a relapsing course is associated with a longer duration of glucocorticoid treatment [<a href="#rid35">35</a>]. Recurrences of polymyalgia rheumatica (PMR) after complete discontinuation of glucocorticoid treatment, months or even years later, also occur [<a href="#rid37">37</a>]. Why PMR is monophasic in some patients and polyphasic in others is unclear. (See <a class="local">'Prognosis'</a> below.)</p><p>Reports on prognostic factors for relapses in PMR are marred by inconsistencies [<a href="#rid1">1</a>]. Relapse has been variably associated with female sex, longer duration of morning stiffness, peripheral arthritis, higher erythrocyte sedimentation rate (ESR) at diagnosis, and persisting elevations of C-reactive protein (CRP), interleukin (IL)-6 levels, and soluble IL-6 receptor levels [<a href="#rid4">4,35,36,38-40</a>]. Increased relapses have also been described with larger initial doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid3">3</a>] and a faster rate of tapering [<a href="#rid3">3,36</a>]. In the absence of defined risk factors for relapses, treatment centers on finding the lowest glucocorticoid dose that controls stiffness and preserves function for the individual patient.</p><p>An approach to the treatment of patients with relapsing or recurrent symptoms is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>If recurrent symptoms develop following discontinuation of glucocorticoids and are accompanied by an elevation in the ESR and/or CRP, glucocorticoids can be resumed at the original dose that managed symptoms. Many patients will recognize the early symptoms of recurring PMR, allowing for a trial of lesser doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> than were used at their initial presentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who relapse while on treatment, the glucocorticoid dose is increased to the lowest dose that achieves symptomatic improvement. Elevations of the acute phase reactants can provide support for the diagnosis of a flare of PMR, but minor flares, requiring only a 1 or 2 mg increase in the <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose, may not be accompanied by such increases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who relapse several times, the interval between dose reductions can be lengthened to six to eight weeks.</p><p></p><p class="headingAnchor" id="H3405235034"><span class="h2">Asymptomatic patients with abnormal testing</span><span class="headingEndMark"> — </span>Elevations in the ESR and/or CRP can occur in the asymptomatic patient. In the absence of symptoms, minor increases do not warrant any change in the glucocorticoid dose. Asymptomatic patients with more significant elevations in the acute phase reactants should be carefully evaluated for symptoms and signs of giant cell arteritis (GCA).</p><p class="headingAnchor" id="H3182931"><span class="h2">Patients who appear glucocorticoid-dependent</span><span class="headingEndMark"> — </span>Difficulties with tapering glucocorticoids in a patient with PMR can arise from a variety of causes.</p><p class="bulletIndent1"><span class="glyph">●</span>One common cause of such difficulty relates to the clinical course of PMR, which, as described above, is prone to relapse and recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another common cause of recurring achiness during the glucocorticoid taper is the symptomatic worsening of prevalent noninflammatory musculoskeletal problems, eg, rotator cuff tendonitis or osteoarthritis. It is important to distinguish recrudescent symptoms due to these local conditions from a bona fide relapse of PMR. This differentiation, however, is sometimes not easy, as patients often experience a degree of symptomatic relief from various degenerative causes of musculoskeletal pain with low-dose glucocorticoids that exceeds responses to previous treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or other analgesia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapsing symptoms, especially if accompanied by distal synovitis, should direct attention to the possibility of a different diagnosis, ie, seronegative rheumatoid arthritis or "late-onset rheumatoid arthritis," and prompt a change in therapeutic paradigm from PMR to so-called late-onset rheumatoid arthritis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibromyalgia-like symptoms, in particular widespread muscle pain associated with stiffness and fatigue, have been reported during the glucocorticoid taper after longstanding therapy in PMR patients, but unlike a true PMR relapse, they are not associated with elevated serum acute phase reactants. Chronic low doses of glucocorticoids are sometimes required to control these manifestations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, diffuse pain can ensue from a rapid taper of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> in a patient who has been on long-term glucocorticoid therapy. (See  <a class="medical medical_review" href="/d/html/7983.html" rel="external">"Glucocorticoid withdrawal", section on 'Recommended tapering regimen'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Limited role for glucocorticoid-sparing therapies</span><span class="headingEndMark"> — </span>The routine use of adjunctive therapy is not recommended because definitive symptomatic control of PMR can usually be achieved with low doses of glucocorticoids and the adverse effects from treatment are often mild. Symptomatic relapses during the course of the glucocorticoid taper are common, and, if managed with only a minor change in the glucocorticoid dose, need not be construed as a failure of treatment.</p><p>Indications for considering the addition of an adjunctive medication to glucocorticoid therapy include preexisting comorbidities (eg, osteoporosis or insulin-requiring or decompensated diabetes mellitus), the development of serious glucocorticoid-related side effects, or multiple relapses of symptoms. In these situations, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) can be used, with the caveat that the use of this drug in contemporary doses used for management of rheumatoid arthritis (up to 25 mg/week) has not been formally studied in PMR. Results from preliminary studies on the use of IL-6 receptor blockade are encouraging, but more controlled studies are needed to assess the efficacy, toxicity, and economic viability of this approach. There are insufficient data to support the use of tumor necrosis factor (TNF) inhibitors or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. Generally similar recommendations are included in the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) guidelines [<a href="#rid15">15,16</a>] and in a systemic review [<a href="#rid41">41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong> – Data from randomized controlled studies on the efficacy of MTX as a glucocorticoid-sparing agent are mixed, though generally favorable results have been reported with regard to cumulative glucocorticoid doses, relapse rates, and time to discontinuation of glucocorticoid treatment [<a href="#rid42">42,43</a>]. Interpretation of a negative controlled study on the use of concurrent MTX is limited by a high dropout rate [<a href="#rid44">44</a>]. These data, however, are limited by several factors including the small number of patients studied and by the relatively low doses of MTX used (in the range of 7.5 to 10 mg/week) compared with contemporary doses (in the range of 20 to 25 mg/week). Also, no study has demonstrated an actual reduction in glucocorticoid-related adverse events in MTX-treated patients compared with patients treated with glucocorticoids alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-6 receptor blockade</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sarilumab – <a class="drug drug_general" data-topicid="113315" href="/d/drug information/113315.html" rel="external">Sarilumab</a> has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with PMR who cannot tolerate glucocorticoid taper [<a href="#rid45">45</a>]. In a randomized trial of 118 patients with relapsing PMR, patients assigned to receive 52 weeks of sarilumab every two weeks (at a dose of 200 mg) plus a 14-week <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> taper had a higher rate of sustained remission than patients assigned to placebo plus a 52-week prednisone taper (28 versus 10 percent), were less likely to relapse once remission was achieved (hazard ratio [HR] 0.56, 95% CI 0.35-0.90) and received a lower median cumulative glucocorticoid dose at 52 weeks (777 versus 2044 mg) [<a href="#rid46">46</a>]. The frequency of serious adverse events was lower among patients assigned to sarilumab (14 versus 21 percent), but more treatment-related discontinuations were observed in the sarilumab group than in the placebo group (12 versus 7 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tocilizumab – In a small, randomized trial of 36 patients with new-onset PMR, patients assigned to weekly subcutaneous <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> had an increased rate of glucocorticoid-free remission compared with patients assigned to placebo (63 versus 12 percent) [<a href="#rid47">47</a>]. There was also a shorter time to relapse for patients in the placebo group. All patients received oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> that was tapered from 20 mg down to 0 mg over 11 weeks. There were five serious adverse events in the placebo group compared with one in the tocilizumab group.</p><p></p><p class="bulletIndent2">In a larger randomized trial of 100 patients with relapsing PMR, patients assigned to intravenous <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> were more likely to achieve a reduction in disease activity and glucocorticoid dose at 24 weeks (67.3 versus 31.4 percent) [<a href="#rid48">48</a>]. Glucocorticoids were discontinued in more patients who had been assigned to tocilizumab (49 versus 19.6 percent). Infections were the most frequent adverse events for both treatment groups (46.9 versus 39.2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rituximab – Findings from a small proof-of-concept trial suggest that there may be role for B cell depletion in the treatment of PMR [<a href="#rid49">49</a>]. Among the 49 patients with PMR who participated in the study, patients who received a single infusion of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in combination with a 17-week glucocorticoid tapering scheme were more likely to achieve glucocorticoid-free remission at 21 weeks compared with those who received the 17-week glucocorticoid tapering scheme alone (48 versus 21 percent; difference 27 percent [one-sided 95% CI 4]; relative risk 2.3 [1.1]) [<a href="#rid49">49</a>]. After one year of follow-up, patients who received a single infusion of rituximab were more likely to have achieved a drug-free remission than patients treated with placebo (47 versus 23 percent) [<a href="#rid50">50</a>]. There were more infusion-related adverse events in the rituximab group. More data with longer-term follow-up are needed to determine whether rituximab may be considered as a glucocorticoid-sparing agent for the treatment of PMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a> – Findings from a small proof-of-concept study suggest that tofacitinib may be effective for the treatment of PMR. In this study, 67 patients with newly diagnosed PMR were randomized to receive treatment with tofacitinib (5 mg twice daily) or to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 15 mg daily (followed by a subsequent taper) [<a href="#rid51">51</a>]. At the end of 12 and 24 weeks, patients had an equivalent response to both therapies, as measured by acute phase reactants (ie, ESR, CRP) and the PMR Activity Score (PMR-AS). More data with longer-term follow-up are needed to determine whether tofacitinib is an effective substitute for glucocorticoids for patients with PMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF inhibitors</strong> – Several studies have failed to demonstrate a significant benefit with TNF inhibitors compared with glucocorticoids. In a randomized trial of 51 patients with newly diagnosed PMR, the use of upfront <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> dosed at 3 mg/kg on weeks 0, 2, 6, 14, and 22 was not more effective than <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus placebo [<a href="#rid52">52</a>]. The proportion of patients in the two groups who were relapse- or recurrence-free was similar at 22 weeks (55 versus 54 percent with placebo) and at 52 weeks (30 versus 37 percent).</p><p></p><p class="bulletIndent1">A randomized double-blind controlled study comparing <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> to placebo in 20 patients with newly diagnosed PMR showed a modest reduction in the PMR activity score in etanercept-treated patients, but the study was only two weeks in duration [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Two small open-label studies, totaling 15 patients, described benefit from adjunctive treatment with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> in patients with relapsing PMR, with reduction or discontinuation of glucocorticoid treatment [<a href="#rid54">54,55</a>]. Other favorable anecdotes have been reported [<a href="#rid56">56</a>]. Given the limited size and quality of these studies, however, and the lack of additional randomized controlled trials, a role for etanercept (or other TNF inhibitors) cannot be endorsed for the management of PMR.</p><p></p><p class="headingAnchor" id="H20"><span class="h1">OTHER THERAPIES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical therapy</strong> – Physical therapy has no role in the initial management of a patient with untreated polymyalgia rheumatica (PMR), as the extent of associated stiffness usually precludes meaningful participation in a program of therapeutic exercise. In an older adult who has become deconditioned, physical therapy can assist with the restoration of fitness once effective treatment for PMR has been implemented.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsteroidal antiinflammatory drugs</strong> – Nonsteroidal antiinflammatory drugs (NSAIDs) have no role in the initial management of PMR. Patients typically report no or minimal symptomatic improvement if these medications have been tried prior to initiation of glucocorticoid therapy.</p><p></p><p class="headingAnchor" id="H23"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>There is no evidence of increased mortality associated with polymyalgia rheumatica (PMR) [<a href="#rid57">57</a>]. PMR is not erosive and does not cause structural damage. Pain and functional limitations are eliminated with low doses of glucocorticoids. Morbidity in PMR most often relates to the longer-term impact of its treatment. Relapses of symptoms commonly respond to minor adjustments in the glucocorticoid dose, and treatment to prevent relapses must be weighed against the risks of drug-related toxicities.</p><p>The heterogeneity of the clinical course commits the clinician to the care of an older adult patient on glucocorticoids for what can be an extended period of time. Guidelines for initial management with glucocorticoids and for subsequent tapering can be outlined, but ultimately, treatment must be flexible and individualized.</p><p class="headingAnchor" id="H3876478735"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117108.html" rel="external">"Society guideline links: Giant cell arteritis and polymyalgia rheumatica"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15532.html" rel="external">"Patient education: Polymyalgia rheumatica and giant cell arteritis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/576.html" rel="external">"Patient education: Polymyalgia rheumatica and giant cell arteritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall approach to therapy</strong> – Polymyalgia rheumatica (PMR) is characterized by a prompt response to glucocorticoids in low to moderate doses  (<a class="graphic graphic_algorithm graphicRef130045" href="/d/graphic/130045.html" rel="external">algorithm 1</a>). The primary goal of therapy is the relief of symptoms. Therapy has not been shown to improve prognosis or prevent progression to giant cell arteritis (GCA, also known as Horton disease, Horton giant cell arteritis, and temporal arteritis). (See <a class="local">'Overall approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> – In all patients with PMR, we recommend initial treatment with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Our practice is to start with a dose of prednisone 15 mg/day. The initial dose of prednisone can be modified depending upon the patient's weight, the severity of symptoms, and comorbidities such as diabetes mellitus, severe hypertension, or heart failure. (See <a class="local">'Initial dose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial dose</strong> – The symptomatic response to glucocorticoid treatment is typically rapid. If symptoms are not well controlled within one week of initiating therapy, the <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose should be increased by 5 mg to a dose of 20 mg/day. Practically all patients with PMR alone will respond to 15 to 20 mg/day of prednisone. Split-dose prednisone can be effective in patients in whom the response to treatment is slow. Persistent aching and stiffness despite the administration of prednisone at these doses mandate pursuit of an alternative diagnosis. (See <a class="local">'Systemic glucocorticoids'</a> above and  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid tapering</strong> – The glucocorticoid dose that suppresses symptoms should be maintained for two to four weeks after aching and stiffness have resolved and can then be gradually reduced every two to four weeks to the lowest dose needed to maintain suppression of symptoms. (See <a class="local">'Glucocorticoid tapering'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients receiving over 10 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>/day, the dose can be lowered by 2.5 mg/day decrements every two to four weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Once the dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is 10 mg/day, further tapering can be done by 1 mg per month, provided the clinical course is stable</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – The clinical response to glucocorticoid therapy is closely monitored, which centers on screening for the presence and/or recurrence of symptoms of PMR or GCA. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) should be measured at baseline and then two months after initiating glucocorticoid therapy. The ESR and CRP are then repeated as indicated every three to six months during glucocorticoid therapy, noting that patients with recurrent relapses often require more frequent laboratory monitoring. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent1">Minor fluctuations in the ESR and/or CRP can occur in the completely asymptomatic patient and alone are not necessarily grounds for intensification of glucocorticoid therapy. Patients with more significant elevations in ESR and/or CRP without an increase in PMR symptoms should be evaluated for other possible diagnoses, especially GCA. (See <a class="local">'Asymptomatic patients with abnormal testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of relapsing or recurrent disease</strong> – Relapse is common, particularly when the glucocorticoid dose is tapered too rapidly. In patients in whom symptoms recur following discontinuation of glucocorticoids and are accompanied by an elevated ESR and/or CRP, glucocorticoids should be resumed at the dose that previously provided control of symptoms. In patients who relapse while on glucocorticoids, the strategy is similar, ie, resumption of the previous effective dose. (See <a class="local">'Management of relapsing or recurrent disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – In most patients, PMR runs a self-limited course, and glucocorticoid therapy can eventually be discontinued. Often, treatment can be stopped after one to two years, but the need for more protracted glucocorticoid therapy is not exceptional. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimizing risks of glucocorticoid therapy</strong> – Patients should also be monitored for adverse effects of glucocorticoids, including osteoporosis, glucose intolerance, and hypertension. (See <a class="local">'Minimizing risks of glucocorticoid therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H1223329159"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William P Docken, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 2015; 74:1808.</a></li><li><a class="nounderline abstract_t">Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48:662.</a></li><li><a class="nounderline abstract_t">Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32:65.</a></li><li><a class="nounderline abstract_t">Lee JH, Choi ST, Kim JS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 2013; 33:1475.</a></li><li><a class="nounderline abstract_t">Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001; 30:260.</a></li><li><a class="nounderline abstract_t">Mackie SL, Hensor EM, Haugeberg G, et al. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 2010; 49:716.</a></li><li><a class="nounderline abstract_t">Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989; 48:658.</a></li><li><a class="nounderline abstract_t">Catoggio W, Soriano ER, Imamura PM. Treatment of polymyalgia rheumatica: lower initial dose. Br J Rheumatol 1991; 30:393.</a></li><li><a class="nounderline abstract_t">Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47:733.</a></li><li><a class="nounderline abstract_t">Cimmino MA, Parodi M, Montecucco C, Caporali R. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 2011; 12:94.</a></li><li><a class="nounderline abstract_t">Hutchings A, Hollywood J, Lamping DL, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007; 57:803.</a></li><li><a class="nounderline abstract_t">Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71:484.</a></li><li><a class="nounderline abstract_t">Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998; 37:189.</a></li><li><a class="nounderline abstract_t">Salvarani C, Cantini F, Olivieri I, et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol 2000; 27:1470.</a></li><li><a class="nounderline abstract_t">Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015; 74:1799.</a></li><li><a class="nounderline abstract_t">Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol 2015; 67:2569.</a></li><li><a class="nounderline abstract_t">Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010; 49:186.</a></li><li><a class="nounderline abstract_t">Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013; 381:63.</a></li><li><a class="nounderline abstract_t">Muratore F, Pazzola G, Pipitone N, Salvarani C. Recent advances in the diagnosis and treatment of polymyalgia rheumatica. Expert Rev Clin Immunol 2016; 12:1037.</a></li><li><a class="nounderline abstract_t">González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet 2017; 390:1700.</a></li><li><a class="nounderline abstract_t">Hernández-Rodríguez J, Cid MC, López-Soto A, et al. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009; 169:1839.</a></li><li><a class="nounderline abstract_t">Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30:17.</a></li><li><a class="nounderline abstract_t">Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36:1286.</a></li><li><a class="nounderline abstract_t">Alvarez-Rodríguez L, Lopez-Hoyos M, Mata C, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 2010; 69:263.</a></li><li><a class="nounderline abstract_t">McCarthy EM, MacMullan PA, Al-Mudhaffer S, et al. Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica. Rheumatology (Oxford) 2013; 52:465.</a></li><li><a class="nounderline abstract_t">Muratore F, Pipitone N, Hunder GG, Salvarani C. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 2013; 31:S86.</a></li><li><a class="nounderline abstract_t">Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 1985; 79:309.</a></li><li><a class="nounderline abstract_t">Cimmino MA, Salvarani C, Macchioni P, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 2008; 26:395.</a></li><li><a class="nounderline abstract_t">Narváez J, Nolla-Solé JM, Clavaguera MT, et al. Temporal arteritis and polymyalgia rheumatica in north-eastern Spain: clinical spectrum and relationship over a 15 year period. Joint Bone Spine 2003; 70:33.</a></li><li><a class="nounderline abstract_t">Liozon E, de Boysson H, Dalmay F, et al. Development of Giant Cell Arteritis after Treating Polymyalgia or Peripheral Arthritis: A Retrospective Case-control Study. J Rheumatol 2018; 45:678.</a></li><li><a class="nounderline abstract_t">Soriano A, Muratore F, Pipitone N, et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 2017; 13:476.</a></li><li><a class="nounderline abstract_t">Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40:1873.</a></li><li><a class="nounderline abstract_t">Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012; 39:552.</a></li><li><a class="nounderline abstract_t">Shbeeb I, Challah D, Raheel S, et al. Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population. Arthritis Care Res (Hoboken) 2018; 70:643.</a></li><li><a class="nounderline abstract_t">Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53:33.</a></li><li><a class="nounderline abstract_t">González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26:1326.</a></li><li><a class="nounderline abstract_t">Docken WP. Polymyalgia rheumatica can recur years after discontinuation of corticosteroid therapy. Clin Exp Rheumatol 2009; 27:S25.</a></li><li><a class="nounderline abstract_t">Weyand CM, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159:577.</a></li><li><a class="nounderline abstract_t">Pulsatelli L, Boiardi L, Pignotti E, et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum 2008; 59:1147.</a></li><li><a class="nounderline abstract_t">Cimmino MA, Parodi M, Caporali R, Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 2006; 1069:315.</a></li><li><a class="nounderline abstract_t">Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016; 315:2442.</a></li><li><a class="nounderline abstract_t">Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23:624.</a></li><li><a class="nounderline abstract_t">Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141:493.</a></li><li><a class="nounderline abstract_t">van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55:218.</a></li><li class="breakAll">KEVZARA (sarilumab) injection, for subcutaneous use. US Food and Drug Administration (FDA) approved product information. Revised February 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf (Accessed on April 10, 2023).</li><li><a class="nounderline abstract_t">Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med 2023; 389:1263.</a></li><li><a class="nounderline abstract_t">Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann Rheum Dis 2022; 81:838.</a></li><li><a class="nounderline abstract_t">Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA 2022; 328:1053.</a></li><li><a class="nounderline abstract_t">Marsman DE, den Broeder N, van den Hoogen, et al. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. The Lancet Rheumatology 2021; 3:E758.</a></li><li><a class="nounderline abstract_t">Bolhuis TE, Marsman DE, den Broeder AA, et al. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol 2023; 5:e208.</a></li><li><a class="nounderline abstract_t">Ma X, Yang F, Wu J, et al. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med 2023; 20:e1004249.</a></li><li><a class="nounderline abstract_t">Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007; 146:631.</a></li><li><a class="nounderline abstract_t">Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 2010; 12:R176.</a></li><li><a class="nounderline abstract_t">Catanoso MG, Macchioni P, Boiardi L, et al. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 2007; 57:1514.</a></li><li><a class="nounderline abstract_t">Corrao S, Pistone G, Scaglione R, et al. Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol 2009; 28:89.</a></li><li><a class="nounderline abstract_t">Aikawa NE, Pereira RM, Lage L, et al. Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clin Rheumatol 2012; 31:575.</a></li><li><a class="nounderline abstract_t">Doran MF, Crowson CS, O'Fallon WM, et al. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29:1694.</a></li></ol></div><div id="topicVersionRevision">Topic 8222 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26359489" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2782976" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630727" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relapse in a population based cohort of patients with polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23184033" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11727839" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20064872" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2782975" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913020" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of polymyalgia rheumatica: lower initial dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3178314" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21569559" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530680" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388996" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9569075" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852273" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26359488" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352874" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910443" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : BSR and BHPR guidelines for the management of polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23051717" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27079756" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recent advances in the diagnosis and treatment of polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28774422" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901135" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of polymyalgia rheumatica: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966209" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8216422" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19254903" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Circulating cytokines in active polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23125391" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24129145" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4036982" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Polymyalgia rheumatica. Duration of therapy and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18578959" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639615" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Temporal arteritis and polymyalgia rheumatica in north-eastern Spain: clinical spectrum and relationship over a 15 year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29545449" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Development of Giant Cell Arteritis after Treating Polymyalgia or Peripheral Arthritis: A Retrospective Case-control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28680132" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Visual loss and other cranial ischaemic complications in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336424" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247343" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28704600" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696567" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381051" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646342" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Polymyalgia rheumatica can recur years after discontinuation of corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090114" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Corticosteroid requirements in polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668607" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855159" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is the course of steroid-treated polymyalgia rheumatica more severe in women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27299619" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730115" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466766" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733437" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733437" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37792612" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35210264" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36125471" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38251523" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37384596" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470831" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20854662" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050171" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946712" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234490" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12180732" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
